---
figid: PMC8120506__etm-22-01-10134-g00
figtitle: Mitochondrial biogenesis signaling pathway is a potential therapeutic target
  for myasthenia gravis via energy metabolism (Review)
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Gallus gallus
pmcid: PMC8120506
filename: etm-22-01-10134-g00.jpg
figlink: /pmc/articles/PMC8120506/figure/f1-ETM-0-0-10134/
number: F1
caption: 'Balance of the energy metabolism triggered by activation of AMPK. AMPK can
  be activated by the upstream kinases LKB1, CAMKK2, TAK1 and high AMP/ADP:ATP ratios,
  which maintain the body''s energy balance by promoting catabolism and inhibiting
  anabolism. () Promoting catabolism: AMPK controls the biogenesis through phosphorylation
  of SIRT1 to activate PGC-1α, thereby affecting the energy metabolism of the body.
  P38 can also activate PGC-1α by phosphorylating ATF2 and MEF2. () Inhibition of
  anabolism: AMPK inhibits glycogen synthesis by inhibiting TBC1D1 to control the
  translation of GLUT4. AMPK inhibits fatty acid synthesis by suppressing ACC and
  SREBP1C. Arrow, activation. Bar-headed line, inhibition. AMPK, AMP-activated protein
  kinase; LKB1, Liver Kinase B1; CAMKK2, calcium/calmodulin dependent protein kinase
  kinase 2; TAK1, TGF-beta-activated kinase 1; SIRT1, sirtuin 1; PGC-1α, proliferator-activated
  receptor γ coactivator 1α; ATF2, activating transcription factor 2; MEF2, myocyte
  enhancer factor 2; GLUT4, glucose transporter type 4; TBC1D1, Tre-2/BUB2/cdc1 domain
  family 1; ACC, acetyl-CoA carboxylase; SREBP1C, sterol-regulatory element binding
  protein lC.'
papertitle: The mitochondrial biogenesis signaling pathway is a potential therapeutic
  target for myasthenia gravis via energy metabolism (Review).
reftext: Lingling Ke, et al. Exp Ther Med. 2021 Jul;22(1):702.
year: '2021'
doi: 10.3892/etm.2021.10134
journal_title: Experimental and Therapeutic Medicine
journal_nlm_ta: Exp Ther Med
publisher_name: D.A. Spandidos
keywords: myasthenia gravis | mitochondria | energy metabolism | mitochondrial biogenesis
  | AMP-activated protein kinase | proliferator-activated receptor γ coactivator 1α
automl_pathway: 0.9311746
figid_alias: PMC8120506__F1
figtype: Figure
organisms_ner:
- Mus musculus
redirect_from: /figures/PMC8120506__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8120506__etm-22-01-10134-g00.html
  '@type': Dataset
  description: 'Balance of the energy metabolism triggered by activation of AMPK.
    AMPK can be activated by the upstream kinases LKB1, CAMKK2, TAK1 and high AMP/ADP:ATP
    ratios, which maintain the body''s energy balance by promoting catabolism and
    inhibiting anabolism. () Promoting catabolism: AMPK controls the biogenesis through
    phosphorylation of SIRT1 to activate PGC-1α, thereby affecting the energy metabolism
    of the body. P38 can also activate PGC-1α by phosphorylating ATF2 and MEF2. ()
    Inhibition of anabolism: AMPK inhibits glycogen synthesis by inhibiting TBC1D1
    to control the translation of GLUT4. AMPK inhibits fatty acid synthesis by suppressing
    ACC and SREBP1C. Arrow, activation. Bar-headed line, inhibition. AMPK, AMP-activated
    protein kinase; LKB1, Liver Kinase B1; CAMKK2, calcium/calmodulin dependent protein
    kinase kinase 2; TAK1, TGF-beta-activated kinase 1; SIRT1, sirtuin 1; PGC-1α,
    proliferator-activated receptor γ coactivator 1α; ATF2, activating transcription
    factor 2; MEF2, myocyte enhancer factor 2; GLUT4, glucose transporter type 4;
    TBC1D1, Tre-2/BUB2/cdc1 domain family 1; ACC, acetyl-CoA carboxylase; SREBP1C,
    sterol-regulatory element binding protein lC.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Atf2
  - Crk
  - Grap2
  - Syp
  - Mapk14
  - Ahsa1
  - Wdtc1
  - Mdga2
  - Mef2c
  - Myef2l
  - Sirt1
  - Ppargc1a
  - Stk11
  - Camkk1
  - Slc2a4
  - Nr2c2
  - Map3k7
  - Tgfb1
  - Ltbp1
  - Acc
---
